APOB and Parkinson disease: Estimates for circulating ApoB was not estimated to affect PD risk by any MR method, and were not substantially different from estimates of an effect of specific inhibition of ApoB function (averaged across any tissue‐specific effects) on PD from drug target models of APOB (see Fig. 1).